Been watching West Pharmaceutical's earnings setup pretty closely, and there's a compelling narrative building around their HVP momentum that feels like it could carry through another quarter. The company's guiding for Q4 revenues in the $790-800M range, which implies just 1-2.3% organic growth on the surface, but that's where the HVP story gets interesting.

Here's what caught my attention: during Q3, management actually raised their full-year HVP growth estimate by 50 basis points, signaling real strength in that portfolio. The HVP Components business alone was generating 48% of total sales in Q3 with 13.3% organic growth year-over-year. That's not small. They're benefiting from strong GLP-1 demand, HVP upgrades, and improving biologics performance. Even with some manufacturing constraints at their Germany facility, I'd expect similar momentum continued into Q4.

On the margin side, this is where it gets juicy. Higher-margin HVP components are driving gross margin expansion. The company's pushing down costs on SmartDose 3.5, and they're actively converting Standard Products business (which was 20% of Q3 sales) into higher-margin HVP components. That conversion strategy should show up in improved profitability for the Proprietary Products segment.

The consensus is calling for $794.3M in revenues (6.1% YoY growth) and $1.83 EPS. One thing to note though: there was a $25M incentive recorded in Q4 2024 for their HVP delivery device business that won't repeat, so they'll need the strength in laminated technology products and Westar/Envision to offset that. The tariff headwind is real too—they're expecting $15-20M impact for the full year.

On the Contract Manufacturing side, they should see some benefit from continued obesity and diabetes device demand, though diagnostic device weakness could be a partial offset.

The Zacks model isn't calling for a beat this time (Earnings ESP sitting at -0.78%), which is interesting given their track record of crushing estimates. But the HVP narrative and margin expansion story still feels like the real takeaway here. If that momentum holds, the multiple could have more room to run regardless of whether they beat by a few cents.